BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23219173)

  • 1. E2F1 apoptosis counterattacked: evil strikes back.
    Pützer BM; Engelmann D
    Trends Mol Med; 2013 Feb; 19(2):89-98. PubMed ID: 23219173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
    Engelmann D; Pützer BM
    Drug Resist Updat; 2010; 13(4-5):119-31. PubMed ID: 20675184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The E2F family and the role of E2F1 in apoptosis.
    Wu Z; Zheng S; Yu Q
    Int J Biochem Cell Biol; 2009 Dec; 41(12):2389-97. PubMed ID: 19539777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.
    Wang Y; Alla V; Goody D; Gupta SK; Spitschak A; Wolkenhauer O; Pützer BM; Engelmann D
    Nucleic Acids Res; 2016 Jan; 44(1):117-33. PubMed ID: 26350215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
    Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
    J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
    Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
    Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.
    Ben Shachar B; Feldstein O; Hacohen D; Ginsberg D
    Mol Cancer Res; 2010 Mar; 8(3):363-72. PubMed ID: 20197383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation.
    Gurtner A; Fuschi P; Martelli F; Manni I; Artuso S; Simonte G; Ambrosino V; Antonini A; Folgiero V; Falcioni R; Sacchi A; Piaggio G
    Cancer Res; 2010 Dec; 70(23):9711-20. PubMed ID: 20952509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR signaling inhibits E2F1-induced apoptosis in vivo: implications for cancer therapy.
    Ginsberg D
    Sci STKE; 2007 Jan; 2007(371):pe4. PubMed ID: 17264315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.
    Powers JT; Hong S; Mayhew CN; Rogers PM; Knudsen ES; Johnson DG
    Mol Cancer Res; 2004 Apr; 2(4):203-14. PubMed ID: 15140942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
    Russell JL; Weaks RL; Berton TR; Johnson DG
    Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dark side of E2F1: in transit beyond apoptosis.
    Engelmann D; Pützer BM
    Cancer Res; 2012 Feb; 72(3):571-5. PubMed ID: 22298593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-mediated regulation of E2F1 in DNA damage-induced cell death.
    Xie Q; Bai Y; Wu J; Sun Y; Wang Y; Zhang Y; Mei P; Yuan Z
    J Recept Signal Transduct Res; 2011 Apr; 31(2):139-46. PubMed ID: 21320024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
    Laine A; Westermarck J
    Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jab1 is a specificity factor for E2F1-induced apoptosis.
    Hallstrom TC; Nevins JR
    Genes Dev; 2006 Mar; 20(5):613-23. PubMed ID: 16481464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E2F1 death pathways as targets for cancer therapy.
    Pützer BM
    J Cell Mol Med; 2007; 11(2):239-51. PubMed ID: 17488475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice.
    Wikonkal NM; Remenyik E; Knezevic D; Zhang W; Liu M; Zhao H; Berton TR; Johnson DG; Brash DE
    Nat Cell Biol; 2003 Jul; 5(7):655-60. PubMed ID: 12833065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death.
    Li Z; Kreutzer M; Mikkat S; Mise N; Glocker MO; Pützer BM
    Proteomics; 2006 Nov; 6(21):5735-45. PubMed ID: 17001603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F1 mediates ectopic proliferation and stage-specific p53-dependent apoptosis but not aberrant differentiation in the ocular lens of Rb deficient fetuses.
    Liu Y; Zacksenhaus E
    Oncogene; 2000 Dec; 19(52):6065-73. PubMed ID: 11146559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.
    Ofir M; Hacohen D; Ginsberg D
    Mol Cancer Res; 2011 Apr; 9(4):440-7. PubMed ID: 21454377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.